TLR4 and gram-negative bacterial infections: Eritoran antagonizes LPS binding to the receptor MD-2 associated with TLR4, and TAK-242 interacts with the Cys-747 residue on intracellular domain of TLR4, thereby blocking inflammatory responses in sepsis specially due to Gram-negative bacterial infection but not other microbes5, 6.